SecBot SecBot
SECBOTREPLAY Home › Report › MRK

MRK · Merck reported Q2 2026 revenue of $16.6B (+5% YoY), beating consensus…

Merck & Co., Inc. · 8-K filed Aug 4, 2026 at 06:47 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Aug 4, 2026 at 06:47 ET

Merck reported Q2 2026 revenue of $16.6B (+5% YoY), beating consensus of $16.37B, and non-GAAP EPS of -$0.13 vs consensus -$0.26 (a 50% beat). The company raised its full-year sales guidance to $66.3B-$67.3B but lowered non-GAAP EPS guidance to $2.66-$2.76 due to $2.31/share charge from the Terns acquisition. Operational strength in oncology (KEYTRUDA QLEX uptake, WINREVAIR +75%) and new product launches (LIPFENDRA approval) was offset by acquisition-related losses and declining legacy franchises (GARDASIL, JANUVIA).

  • Q2 2026 sales $16,607M (+5% YoY; +4% ex-FX)
  • Non-GAAP EPS -$0.13 vs consensus -$0.26 (beat by 50%)
  • KEYTRUDA/KEYTRUDA QLEX combined sales $8,366M (+5% YoY); KEYTRUDA QLEX contributed $463M
  • WINREVAIR sales $588M (+75% YoY)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access